Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka
Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-136593 · Präparat HOS-097888
Tenofovir: AUC: ↑ 39% (↑ 33 to ↑ 44) Cmax: ↑ 55% (↑ 45 to ↑ 66) Cmin: ↑ 52% (↑ 45 to ↑ 59) Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations of (400 mg/100 mg q.d.) + AUC: ↓ 29% (↓ 36 to ↓ 22) tenofovir resulting from co Lopinavir/Ritonavir Cmax: ↓ 41% (↓ 51 to ↓ 29) administration of tenofovir disoproxil, (800 mg/200 mg q.d.) + sofosbuvir/velpatasvir and Emtricitabine/Tenofovir disoproxil GS-3310072: lopinavir/ritonavir may increase (200 mg/245 mg q.d.) AUC: ↔ adverse reactions related to tenofovir Cmax: ↔ disoproxil, including renal disorders. Cmin: ↔ The safety of tenofovir disoproxil when used with sofosbuvir/velpatasvir and a Velpatasvir: pharmacokinetic enhancer (e.g. AUC: ↔ ritonavir or cobicistat) has not been Cmax: ↓ 30% (↓ 41 to ↓ 17) established. Cmin: ↑ 63% (↑ 43 to ↑ 85) The combination should be used with Lopinavir: caution with frequent renal monitoring AUC: ↔ (see section 4.4). Cmax: ↔ Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-31T12:47:00Z · SHA-256 bff22a935481266901d4c92f1163f09cb1d50edd80ede33ac1750318fed62b8d · Passage ec6779987ebb807cf1e47d9498c55d6d051f360306908e03c07c55b2e7dd0d68 · Zeichen 23000–24841 im Abschnitt